Probe developer Neoprobe has debuted Quantix, the first commercial launch in its Cardiosonix blood-flow measurement product portfolio.
The initial Quantix release, Quantix/ND, is an angle-independent ultrasound probe designed to allow neurosurgeons, neurologists, intensive care units, and emergency room physicians to noninvasively measure cerebral blood flow in real time, according to the Dublin, OH-based vendor. Quantix/ND can also be used for blood-flow measurement in vascular labs, Neoprobe said.
The next Quantix product, Quantix/OR, allows for intraoperative blood-flow measurement. Neoprobe said that it hopes to complete the CE Mark clearance process for Quantix/OR by the end of 2002. A 510(k) application will be filed with the Food and Drug Administration shortly thereafter, Neoprobe said.
By AuntMinnie.com staff writersNovember 21, 2002
Related Reading
Neoprobe’s Q3 revenues sag, November 13, 2002
Neoprobe gets clearance for FlowGuard, February 28, 2002
Neoprobe reports second year of profitability, February 25, 2002
Neoprobe closes Biosonix purchase, January 4, 2002
Neoprobe moves closer to Biosonix purchase, December 11, 2001
Copyright © 2002 AuntMinnie.com
